INDIVIDUAL ASSIGNMENT

ACADEMIC WRITING
1st Year / 2nd Semester / 2023 / FMUI 2023
Name : Fayara Aretha Kunaefi
NPM : 2306253215

Unraveling the Complexity of Pulmonary Mycosis: Diagnosis, Management,

and Future Perspectives

Pulmonary mycosis, an infection arising from the growth and reproduction of

pathogens, particularly fungi within the lungs, can impact the respiratory tract, lung
tissues, and potentially spread to other body parts under worsening conditions. Fungi
such as Candida, Aspergillus, and Histoplasma are commonly associated with
pulmonary mycosis cases, varying in severity and symptoms based on the specific
fungus and individual health conditions.1

Pulmonary mycosis exemplifies systemic fungal infections, a classification targeting

organs within the body, including the lungs. Systemic fungal spread can occur
through the bloodstream or lymphatic system, involving two types of fungi: systemic
pathogenic fungi and opportunistic fungi. Pulmonary mycosis is predominantly
caused by opportunistic fungi, non-pathogenic in a healthy state but turning
pathogenic when the immune system is compromised. Systemic fungal infections
may originate from the lungs through inhalation or endogenous flora leakage from
the digestive tract, potentially spreading to other organs. Such infections are serious,
carrying high mortality rates if not promptly treated. Pulmonary candidiasis, caused
by Candida, is a common opportunistic pulmonary fungal infection in Indonesia. The
pathogenesis of pulmonary mycosis illustrates the growth and impact of fungi on the
host organism. Using pulmonary candidiasis as an example again, opportunistic
fungi's pathogenesis occurs as colonization increases, triggered by factors like
mucosa or skin barrier damage, tissue damage, or immune system dysfunction.
Invasive fungal invasion can lead to various health complications, emphasizing the
importance of lymphocytes and cell-mediated immunity.2
Several risk factors, including medical conditions like HIV, cancer, chronic
neutropenia, or organ transplantation, elevate the risk of pulmonary mycosis.3 Other
common factors influencing poor prognosis include age, failure to eliminate the
fungus, and malnutrition. Even influenza can serve as a risk factor for invasive
pulmonary mycosis, significantly increasing mortality rates in co-infection cases.
Clinical manifestations of mycosis vary, encompassing symptoms like persistent
cough, difficulty breathing, fever, chest pain, pleural effusion, fatigue, weight loss,
and weakness. Accurate diagnosis requires a comprehensive medical examination by
an experienced doctor due to the nonspecific nature of these symptoms. Diagnosis
involves a combination of clinical evaluation, laboratory tests, and sometimes
invasive procedures.4

Due to its nonspecific symptoms, the general diagnosis of pulmonary mycosis

remains challenging. Therefore, diagnosing pulmonary mycosis requires a
combination of clinical evaluation, laboratory tests, and sometimes invasive
procedures. As part of the diagnosis, doctors may conduct an in-depth medical
interview to understand the patient's health history, including experienced symptoms,
travel history, and risk factors such as underlying medical conditions. If a lung biopsy
is performed, the collected tissue will be examined under a microscope
(histopathology) to detect signs of fungal invasion and other pathological changes.
Radiological examinations such as X-rays or chest CT scans may be used to observe
structural changes in the lungs (such as nodules, cavities, or infiltrates).5 Doctors
may also ask patients to provide sputum samples for culture to identify the type of
fungus causing the infection. Fungal species can also be identified using molecular
techniques such as PCR (polymerase chain reaction). In some cases, bronchoscopy
may be performed. For systemic candidiasis, blood culture is the primary diagnostic
tool.6

The prognosis of pulmonary mycosis can vary significantly depending on multiple

factors. For example, pulmonary candidiasis, caused by the Candida fungus, falls
under the category of systemic candidiasis. This type of candidiasis has a death rate
of 30-40% and is generally correlated with the level of immunosuppression and
underlying diseases. However, Mucocutaneous candidiasis, a type of candidiasis
primarily affecting mucous membranes and the skin, has a very good prognosis with
minimal morbidity and mortality.7 Therefore, it is essential to remember that many
factors influence prognosis, and each case may differ. Under the supervision of an
experienced doctor, patients and the medical team must collaborate to plan and
implement treatment that improves recovery chances. In some cases, pulmonary
mycosis can be extremely serious, while in others, with early diagnosis and proper
treatment, the prognosis can be better.

In conclusion, pulmonary mycosis represents a complex and potentially serious

health challenge, demanding meticulous diagnostic approaches and targeted
treatments. The diverse manifestations of these fungal infections, coupled with their
association with prevalent health conditions and immunocompromised states,
underscore the critical need for early detection and comprehensive management.
The collaboration between patients and healthcare professionals, along with ongoing
research efforts, remains pivotal in advancing our understanding and refining
treatment strategies. By embracing a holistic approach and prioritizing preventive
measures, we can work towards minimizing the impact of pulmonary mycosis on
public health and improving overall patient outcomes.
 Reference List
1. World Health Organization Indonesia. TB day 2021 [Internet]. www.who.int.
World Health Organization; 2021 [cited 2024 Feb 18]. Available from:
https://www.who.int/indonesia/news/campaign/tb-day-2021
2. Mba IE, Nweze EI. Mechanism of candida pathogenesis: revisiting the vital
drivers. Eur. J. Clin. Microbiol. [Internet]. 2020 May 6 [cited 2024 Feb
18];39(10):1797–819. Available from: https://link.springer.co
m/article/10.1007/s10096-020-03912-w
3. White PL, Dhillon R, Hughes H, Wise MP, Backx M. COVID-19 and fungal
infection: the need for a strategic approach. The Lancet Microbe [Internet].
2020 Sep [cited 2024 Feb 18];1(5):e196. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832937/
4. Guo M, Tong Z. Risk factors associated with invasive pulmonary mycosis
among severe influenza patients in beijing city, china. Int. J. Gen. Med.
[Internet]. 2021 Oct 29 [cited 2024 Feb 18]; 14:7381–90. Available from:
https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8565897/
5. Reddy GK, Padmavathi AR, Nancharaiah YV. Fungal infections: pathogenesis,
antifungals and alternate treatment approaches. Curr. Res. Microb. Sci.
[Internet]. 2022 [cited 2024 Feb 18];3. Available from:
https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC9325902/
6. Valente P, Ferreira J, Pinto I, Medeiros N, Oliveira P, Castro E, et al.
Management of laryngeal candidiasis: an evidence-based approach for the
otolaryngologist. Eur. Arch. Oto-Rhino-L [Internet]. 2020 Feb 27 [cited 2024
Feb 18];277(5):1267–72. Available from:
https://pubmed.ncbi.nlm.nih.gov/32107617/
7. Hidalgo JA. Candidiasis follow-up: further outpatient care, further inpatient
care, inpatient & outpatient medications. eMedicine [Internet]. 2023 Jun 13
[cited 2024 Feb 18]; Available from:
https://emedicine.medscape.com/article/213853-followup?form=fpf